证券代码：300314 证券简称：戴维医疗 公告编号：2025-016 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度业绩说 明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者 可 于 2025 年 4 月 15 日（星期 二 ） 15:00 前 访 问 （https://company.cnstock.com/wtzj/300314），或扫描下方二维码， 进入问题征集专题页面。公司将在 2024 年度业绩说明会上，对投资者普 遍关注的问题进行回答。 宁波戴维医疗器械股份有限公司 关于举行2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）已于2025年4 月 9 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露了《2024年年度报告全文》及《2024 年年度报告摘要》。为便于广大投资者更深入全面地了解公司经营情况， 公司将于2025年4月16日（星期三）15:00至17:00在上海证券报·中国证 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-022 宁波戴维医疗器械股份有限公司 关于召开2024年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届董事会 第十一次会议决定于2025年5月6日（星期二）召开2024年度股东大会，本 次股东大会采取现场投票和网络投票相结合的方式召开，现将会议有关事 项通知如下： 一、召开会议的基本情况 1、会议届次：2024 年度股东大会 2、会议召集人：公司第五届董事会 （1）现场表决：包括本人出席及通过填写授权委托书授权他人出席。 3、会议召开的合法、合规性：本次股东大会的召集和召开符合《公 司法》《上市公司股东大会规则》等法律、法规和《公司章程》的有关规 定。 4、会议召开日期、时间： 现场会议召开时间：2025 年 5 月 6 日（星期二）14:00 网络投票时间： (1)通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 6 日的交易时间，即 9:15-9:25,9:30-11:30 和 13:00-15:00 ...

二、会议审议情况 经与会董事认真审议，本次会议以记名投票的表决方式表决通过了以 下决议： 1、审议通过《关于 2024 年度总经理工作报告的议案》 证券代码：300314 证券简称：戴维医疗 公告编号：2025-013 宁波戴维医疗器械股份有限公司 第五届董事会第十一次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届董事会 第十一次会议于2025年4月7日上午9:00在公司会议室以现场会议的方式 召开。应参加表决董事9人，实际参加表决董事9人，符合《公司法》和《公 司章程》等相关法律法规的有关规定。本次董事会会议通知已于2025年3 月27日以专人送达方式通知全体董事。董事长陈再宏先生召集和主持了本 次会议，公司监事、高管列席了会议。 本议案以 9 票同意、0 票反对、0 票弃权获得通过。 2、审议通过《关于 2024 年度董事会工作报告的议案》 并将在公司 2024 年度股东大会上进行述职。董事会依据独立董事出具的 《独立董事独立性自查情况表》，编写了《董事会关于独立董事 ...

关于2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于2025年4月7 日召开了第五届董事会第十一次会议及第五届监事会第十一次会议，审议 通过了《关于2024年度利润分配预案的议案》，本议案尚需提交公司2024 年年度股东大会审议。 一、审议程序 1、董事会意见 董事会认为：公司2024年度利润分配预案是基于公司的实际经营情况 做出，符合相关法律、法规以及《公司章程》等有关规定，有利于公司的 持续稳定发展，更好地维护全体股东的利益。董事会同意公司2024年度利 润分配预案，并同意将该议案提交公司2024年度股东大会审议。 2、监事会意见 证券代码：300314 证券简称：戴维医疗 公告编号：2025-015 宁波戴维医疗器械股份有限公司 三、现金分红方案的具体情况 | 1、分红预案不触及其他风险警示情形 | | --- | | 项目 | 2024年度 | 2023年度 | 2022年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 25,056 ...

Financial Performance - The company's revenue and profit have significantly declined due to industry policies and market demand factors, with investment income down year-on-year[5]. - The profit distribution plan approved by the board is a cash dividend of 0.87 RMB per 10 shares, with no bonus shares issued[6]. - The company reported a normal operation status with no significant adverse changes in core competitiveness and major financial indicators[5]. - The company has a total of 288 million shares outstanding, which is the basis for the dividend distribution[6]. - The company's operating revenue for 2024 was ¥527,026,028.11, a decrease of 14.76% compared to ¥618,298,238.74 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥57,263,314.13, down 61.21% from ¥147,610,911.51 in 2023[23]. - The net cash flow from operating activities decreased by 30.57% to ¥93,866,811.14 in 2024 from ¥135,198,386.01 in 2023[23]. - Basic earnings per share for 2024 were ¥0.2, a decline of 60.78% compared to ¥0.51 in 2023[23]. - Total assets at the end of 2024 increased by 2.62% to ¥1,410,082,914.70 from ¥1,374,082,918.93 at the end of 2023[23]. - The company reported a weighted average return on equity of 4.91% for 2024, down from 13.33% in 2023, a decrease of 8.42%[23]. - The company experienced a significant drop in net profit excluding non-recurring gains and losses, which was ¥52,197,201.35 in 2024, down 59.39% from ¥128,522,581.21 in 2023[23]. - The company reported total revenue of 527.03 million yuan, a decrease of 14.76% year-on-year, with net profit attributable to shareholders of 57.26 million yuan, down 61.21% from the previous year[96]. Market and Industry Trends - The medical device industry is supported by national policies aimed at enhancing innovation and reducing costs, which benefits the company's operations[33]. - The implementation of the three-child policy and supportive measures is expected to stimulate consumer demand, further boosting the medical device industry[34]. - The "14th Five-Year" National Medical Security Plan aims to reduce drug and medical consumables prices through centralized procurement, enhancing service quality and operational efficiency in public hospitals[35]. - The "14th Five-Year" Medical Equipment Industry Development Plan focuses on seven key areas, including diagnostic and therapeutic equipment, aiming to enhance China's competitiveness in the global medical equipment market by 2025[37]. - The demand for medical devices is expected to rise due to increasing disposable income, aging population, and enhanced medical insurance coverage in China[49]. - The infant care equipment market is driven by the increasing number of high-risk pregnancies and the growing awareness of infant health care[51]. Product Development and Innovation - The company has developed third-generation infant care equipment, with some products reaching fourth-generation technology levels, featuring improved control precision, reduced energy consumption, and enhanced reliability[52]. - The company is actively developing emergency surgical ICU products, including emergency integrated machines and emergency ventilators, to capture market opportunities[59]. - The company is leveraging its accumulated R&D and sales resources to rapidly advance the development of emergency surgical ICU products, aiming to establish a strong market presence[59]. - The company has developed the BM-200 series transcutaneous bilirubin meters, which improve measurement accuracy and adaptability across different patient groups, enhancing competitiveness in the high-end market[64]. - The company has launched the first domestic disposable electric cutting stapler in 2018 and the world's first intelligent fully automatic turning stapler in 2022, enhancing its core competitiveness[68]. - The company is focusing on high-value consumables in the large surgical market, continuously optimizing minimally invasive surgical instruments[71]. - The company is advancing the development of a dual optical path transcutaneous jaundice meter to improve measurement accuracy[123]. - The company is developing a new medical device for neonatal jaundice treatment, expected to emit visible light in the wavelength range of 400nm to 550nm[17]. Research and Development - R&D investment totaled 55.46 million yuan, accounting for 10.52% of revenue, supporting innovation and development[70]. - The company holds a total of 254 patents, including 64 invention patents, 138 utility model patents, and 52 design patents, providing effective technical support for sustainable development[70]. - The company is enhancing its product development capabilities through industry-academia-research cooperation, focusing on high-performance medical devices and innovative pediatric care equipment[88]. - The company is actively pursuing regulatory approvals for multiple new products, with several expected to be registered by 2029, indicating a robust pipeline for future growth[132]. Financial Management and Cash Flow - The net cash flow from operating activities for 2024 was ¥93,866,811.14, a decrease of 30.57% compared to ¥135,198,386.01 in 2023, primarily due to a reduction in cash received from product sales[137]. - The total cash inflow from operating activities in 2024 was ¥621,980,391.67, down 10.31% from ¥693,450,206.88 in 2023[137]. - The total cash outflow from operating activities in 2024 was ¥528,113,580.53, a decrease of 5.40% compared to ¥558,251,820.87 in 2023[137]. - The company experienced a significant decline in net cash flow from operating activities compared to net profit for the year, indicating a major discrepancy[138]. - Cash and cash equivalents decreased by 17.10%, from 571,365,961 to 345,230,914, reflecting a significant reduction in liquidity[145]. - The company reported a significant increase in construction in progress, rising from 53,953,308.6 to 171,744,678, an increase of 8.25% in total asset allocation[145]. Strategic Outlook and Future Plans - The company is committed to complying with international quality standards and regulations, ensuring that its products meet high-quality requirements, which has earned widespread market recognition[88]. - The company aims to enhance its marketing strategy by closely monitoring the development trends in its key segments and adjusting product branding strategies to meet clinical needs[169]. - The company plans to increase R&D investment in 2025, focusing on integrating AI, big data, and IoT technologies into product design to improve precision, convenience, and safety[170]. - The company is exploring potential acquisitions to bolster its product portfolio and expand its operational capabilities[127]. - The company is actively pursuing strategic partnerships to enhance its product development and market reach[127]. Risks and Challenges - The company faces regulatory risks in the medical device industry, which could impact operations if compliance with domestic and international standards is not maintained[174]. - Increased competition in the medical device sector poses a risk, with potential impacts from international companies employing aggressive pricing and marketing strategies[175]. - The continuous decline in newborn birth rates in China is leading to decreased demand for infant care equipment, directly impacting the company's business performance[178]. - Fluctuations in raw material prices significantly impact the company's gross margin, with potential risks to profitability if prices rise sharply[180]. - As the company expands its scale, particularly in overseas markets, it faces increased management challenges and is focusing on strengthening internal systems to ensure smooth operations[181].

证券代码：300314 证券简称：戴维医疗 公告编号：2025-009 宁波戴维医疗器械股份有限公司 关于全资孙公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资孙公司宁 波甬星医疗仪器有限公司于近日收到浙江省药品监督管理局颁发的2项《医 疗器械注册证》，具体如下： 一、医疗器械注册证的具体情况 1、一次性腔镜用电动切割吻合器及组件 批准日期：2025年04月01日 有效期至：2030年03月31日 注册分类：Ⅱ类 适用范围：适用于腔镜下消化道重建及脏器切除手术中的残端或切口 的闭合。 型号、规格： 器身型号规格：YDCE46、YDSE46、YDLE46、YDCE60、YDSE60、YDLE60； 组件型号规格：YDCR46M、YDCR46W、YDCR46B、YDCR46Y、YDCR46G、YDCR60M、 YDCR60W、YDCR60B、YDCR60Y、YDCR60G、YDCR60H、YTCR46M、YTCR46W、YTCR46B、 YTCR46Y、YTCR46G、YTCR6 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-008 宁波戴维医疗器械股份有限公司 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司于近日收到浙江省药品监督管理局颁发的1 项《医疗器械注册证》，具体如下： 三、对公司的影响 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提 高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 四、风险提示 目前尚无法预测该等产品对公司未来营业收入的影响，敬请投资者注 意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 一、医疗器械注册证的具体情况 二、新产品的市场状况 一次性使用脐带剪夹器为无菌医疗手术器械，操作时将切割和夹闭两 个步骤同时进行，一次性完成脐带的切割和夹紧工作，操作简单方便，不 牵拉脐带可避免对新生儿伤害，两端同时断脐，无溅血危险，避免医务人 员被感染。该产品可应用于妇产科，具有较好的应用前景。 产品名称：一次性使用脐带剪夹器 型号、规格：F3 ...

4月1日，戴维医疗今日收盘12.77元，上涨3.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到41.73倍，总市值36.78亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入4.03亿元，同比-12.21%；净利润6330.79万元， 同比-48.44%，销售毛利率56.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)81戴维医疗41.7324.923.1336.78亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11 ...

Core Viewpoint - David Medical's stock closed at 12.39 yuan, down 2.21%, with a rolling PE ratio of 40.49 times and a total market value of 3.568 billion yuan, indicating a relatively high valuation compared to the industry average [1] Company Overview - Ningbo David Medical Equipment Co., Ltd. specializes in obstetric and pediatric care equipment and minimally invasive surgical instruments, with key products including infant incubators, radiant warmers, jaundice treatment devices, jaundice detection devices, and minimally invasive surgical instruments [1] - The company has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology and is one of the first in the industry to obtain CMDC and CE certifications [1] - David Medical has received multiple awards for its products at domestic and international exhibitions, with several technologies being industry-leading or first in the country [1] Financial Performance - For the third quarter of 2024, the company reported operating revenue of 403 million yuan, a year-on-year decrease of 12.21%, and a net profit of 63.31 million yuan, down 48.44% year-on-year, with a gross profit margin of 56.78% [1] Industry Comparison - The average PE ratio for the medical device industry is 45.22 times, with a median of 32.57 times, positioning David Medical at the 81st rank within the industry [2] - The company's static PE ratio is 24.17 times, and its price-to-book ratio is 3.04 [2]